Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map.
暂无分享,去创建一个
N. Zhao | A. Stoffel | P. Wang | J. Eisenbart | R. Espinosa | R. Larson | M. L. Le Beau | M. Beau | Pauline W. Wang | Archontoula Stoffel | Rafael Espinosa | Richard A. Larson | James D. Eisenbart
[1] Iscn. International System for Human Cytogenetic Nomenclature , 1978 .
[2] J. Rowley,et al. The Fourth International Workshop on Chromosomes in Leukemia: a prospective study of acute nonlymphocytic leukemia. Chicago, Illinois, U.S.A., September 2-7, 1982. , 1984, Cancer genetics and cytogenetics.
[3] G. Tricot,et al. The 5q-anomaly. , 1985, Cancer genetics and cytogenetics.
[4] R. Larson,et al. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] S. Nimer,et al. The 5q- abnormality. , 1987, Blood.
[6] R. Larson,et al. Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo. , 1988, Leukemia.
[7] K. Sadhu,et al. Human homolog of fission yeast cdc25 mitotic inducer is predominantly expressed in G2. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[8] E. Green,et al. Fluorescence in situ hybridization of YAC clones after Alu-PCR amplification. , 1992, Genomics.
[9] R. Espinosa,et al. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[10] D. Liebermann,et al. The zinc finger transcription factor Egr-1 is essential for and restricts differentiation along the macrophage lineage , 1993, Cell.
[11] B. Johansson,et al. Cytogenetic deletion maps of hematologic neoplasms: Circumstantial evidence for tumor suppressor Loci , 1993, Genes, chromosomes & cancer.
[12] D. Oscier,et al. Allelic loss of IRF1 in myelodysplasia and acute myeloid leukemia: retention of IRF1 on the 5q- chromosome in some patients with the 5q- syndrome , 1993 .
[13] A. Knudson,et al. Antioncogenes and human cancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[14] al. et,et al. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia , 1993, Science.
[15] A. Levine. The tumor suppressor genes. , 1993, Annual review of biochemistry.
[16] J. Boultwood,et al. The 5q-syndrome. , 1994, Blood.
[17] J. Rowley,et al. Sequence-independent amplification and labeling of yeast artificial chromosomes for fluorescence in situ hybridization. , 1994, Cytogenetics and cell genetics.
[18] V. Buckle,et al. Molecular mapping of uncharacteristically small 5q deletions in two patients with the 5q- syndrome: delineation of the critical region on 5q and identification of a 5q- breakpoint. , 1994, Genomics.
[19] J. Rowley,et al. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. , 1994, Blood.
[20] T. Rabbitts,et al. Chromosomal translocations in human cancer , 1994, Nature.
[21] P. Sanseau,et al. Two simple procedures for releasing chromatin from routinely fixed cells for fluorescence in situ hybridization. , 1994, Cytogenetics and cell genetics.
[22] P. Nowell,et al. Physical mapping of the minimal region of loss in 5q- chromosome. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[23] E. Green,et al. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. , 1996, Blood.
[24] D. Le Paslier,et al. A yeast artificial chromosome-based map of the region of chromosome 20 containing the diabetes-susceptibility gene, MODY1, and a myeloid leukemia related gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[25] R. Larson,et al. Therapy-related myeloid leukemia. , 2008, Seminars in oncology.
[26] P. Deloukas,et al. A Gene Map of the Human Genome , 1996, Science.
[27] J. Massagué,et al. A human Mad protein acting as a BMP-regulated transcriptional activator , 1996, Nature.
[28] J. Karp,et al. The secondary leukemias: challenges and research directions. , 1996, Journal of the National Cancer Institute.